---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-24-000016"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:36:00.603188+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences FY2023 revenue $219.8M (+60%); Q4 $66.1M; guides 2024 $235-240M

## Summary
- Full-year 2023 revenue $219.8M (+60% YoY); total test reports 70,429 (+59%). Q4 revenue $66.1M (+72% YoY).
- Net loss $57.5M in 2023 vs. $67.1M in 2022; Q4 net loss $2.6M vs. $20.6M. Adjusted EBITDA $(4.4)M year, $9.4M Q4.
- Cash, cash equivalents and marketable securities $243.1M at Dec 31, 2023.
- TissueCypher test reports +328% YoY; DecisionDx-SCC +92%; IDgenetix +236%.
- 2024 revenue guidance: $235-240 million; management cites strong commercial momentum.

## SEC filing metadata
- accession: 0001447362-24-000016
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736224000016/0001447362-24-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736224000016/cstl-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-24-000016
- JSON: https://secwatch.observer/filing/0001447362-24-000016.json
- Plain text: https://secwatch.observer/filing/0001447362-24-000016.txt

## Key facts
- Earnings Releases
  CASTLE BIOSCIENCES INC reported the fourth quarter and year ended December 31, 2023 results: revenue $219.8 million, net income $57.5 million.
  - Period: the fourth quarter and year ended December 31, 2023
  - Revenue: $219.8 million
  - Net income: $57.5 million
  - Result: reported results
  source text: in such filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447362/000144736224000016/0001447362-24-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.